Molecular Partners Ag (MOLN) Non Operating Income (2022 - 2025)
Molecular Partners Ag (MOLN) posted quarterly Non Operating Income of -$3.7 million for Q2 2025, down 174.24% year-on-year from $5.0 million in Q2 2024, and down 174.24% on a QoQ basis from $5.0 million in Q2 2024.
Molecular Partners Ag (MOLN) Non Operating Income (2022 - 2025) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Non Operating Income for 4 consecutive years, with -$3.7 million the latest figure, recorded in Q2 2025.
- Quarterly Non Operating Income fell 174.24% year-over-year to -$3.7 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $3.5 million (changed N/A YoY) and the FY2025 annual result came in at -$4.4 million, down 153.84% from the prior year.
- Non Operating Income slipped to -$3.7 million in Q2 2025 per MOLN's latest filing, from $5.0 million in the prior quarter.
- Over the last five years, Non Operating Income for MOLN reached as high as $5.0 million in Q2 2024 and fell as low as -$3.7 million in Q2 2025.
- A 4-year average of $868660.9 and a median of $1.1 million in 2023 frame the typical range for Non Operating Income.
- Annual changes were most pronounced in 2024 — Non Operating Income surged 1353.87% — and 2025, when it sank 174.24%.
- Year by year, Non Operating Income stood at $1.8 million in 2022, then tumbled by 81.25% to $344774.4 in 2023, then jumped by 1353.87% to $5.0 million in 2024, then plunged by 174.24% to -$3.7 million in 2025.
- According to Business Quant data, Non Operating Income over the past three periods registered -$3.7 million, $5.0 million, and $344774.4 for Q2 2025, Q2 2024, and Q2 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -9.22 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 188.30 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | 5.75 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -8.59 Mn |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | -3.72 Mn |
| Jun 30, 2024 | 5.01 Mn |
| Jun 30, 2023 | 344,774.42 |
| Jun 30, 2022 | 1.84 Mn |